Cutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and Digital Assessment Tools Used Today
BOSTON and NEW YORK, April 14, 2025 /PRNewswire/ — Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home blood draw diagnostics and drug delivery systems/patches: combining time synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk assessment.
Since 2019, patients, healthcare systems, pharmaceutical companies, medtech firms, and direct-to-consumer (DTC) clinical trials have increasingly adopted home-based digital care. However, widespread adoption has been hindered by challenges in accuracy, reliability, cost, workflow integration, and limited access to actionable data and interoperability. These barriers have led to frustration and underutilization, highlighting the urgent need for more seamless and effective solutions in remote healthcare.
Nanowear is transforming home-based cardiometabolic healthcare with end-to-end FDA approved cloth nanotechnology and AI diagnostics, SimpleSense™, delivering a full cardiometabolic assessment and continuous picture of individualized health through the use of an AI digital diagnostic platform, while the patient is in the comfort of their own home.
